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Abstract
There is a growing interest in using vaccination with CNS antigens to induce autoreactive T cell responses that home to
damaged areas in the CNS and ameliorate neurodegenerative disease. Neuroprotective vaccine studies have focused on
administering oligodendrocyte antigens or CopaxoneH in complete Freund’s adjuvant (CFA). Theoretical considerations,
however, suggest that vaccination with a neuronal antigen may induce more robust neuroprotective immune responses.
We assessed the neuroprotective potential of vaccines containing tyrosine hydroxylase (a neuronal protein involved in
dopamine synthesis) or CopaxoneH in CFA in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of
Parkinson’s disease. Surprisingly, we observed that the main beneficial factor in these vaccines was the CFA. Since the major
immunogenic component in CFA is Mycobacterium tuberculosis, which closely related to the bacille Calmette-Gue´rin (BCG)
that is used in human vaccines, we tested BCG vaccination in the MPTP mouse model. We observed that BCG vaccination
partially preserved markers of striatal dopamine system integrity and prevented an increase in activated microglia in the
substantia nigra of MPTP-treated mice. These results support a new neuroprotective vaccine paradigm in which general
(nonself-reactive) immune stimulation in the periphery can limit potentially deleterious microglial responses to a neuronal
insult and exert a neurorestorative effect in the CNS. Accordingly, BCG vaccination may provide a new strategy to augment
current treatments for a wide range of neuropathological conditions.
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Introduction
Vaccination with CNS antigens can induce autoreactive T cell
responses that home to sites of injury in the CNS and can inhibit
neuronal degeneration in different models of neurological disease
and injury, including spinal cord and head injury, Parkinson’s
disease, Alzheimer’s disease, amyotrophic lateral sclerosis, gluta-
mate toxicity, and glaucoma (reviewed in [1,2]). It is thought that
immunization activates CNS-reactive T cells that enter the CNS,
secrete neurosupportive factors (e.g., neurotrophins and brain-
derived neurotrophic factor) and shift the phenotype of resident
microglia to one that is more neurosupportive [3,4]. The initial
studies of this therapeutic strategy immunized animals with
oligodendrocyte antigens such as myelin basic protein (MBP)
(e.g., [5,6]). Since autoimmunity to oligodendrocyte antigens can
lead to a multiple sclerosis (MS)-like disease in experimental
animals, subsequent studies of neuroprotective vaccines have
focused on vaccinating with CopaxoneH (e.g., [7,8,9,10]).
CopaxoneH is a mixture of synthetic polypeptides composed of
four amino acids in a random sequence dissolved in an aqueous
solution. Frequent CopaxoneH injection induces regulatory T cell
responses that have partial cross-reactivity with myelin antigens
[11] and this treatment has been approved as a therapy for
relapsing-type MS. The vast majority of neuroprotective vaccine
studies in animal models of neuropathological disorders have,
however, administered myelin antigens or CopaxoneH in complete
Freund’s adjuvant (CFA), an adjuvant that is unsuited for human
use. There have been few reports of adjuvant-free CopaxoneH
having beneficial effects in animal models of neuropathological
disorders other than MS [12,13].
Our previous studies of antigen-based vaccine therapies for
inhibiting autoimmune disease have shown that the ability of a
vaccine to induce protective T cell responses depends critically on
which self-antigen is administered [14,15,16]. This is because each
self-antigen has a unique expression pattern and impact on T cell self-
tolerance induction. Accordingly, self-antigens have different immu-
nogenicities and should vary in their ability to induce neuroprotective
T cell responses. Random copolymers as CopaxoneH may not be
optimal immunogens for inducing neuroprotective T cell responses
since only a small portion of the induced T cell response may be
capable of cross-reacting with CNS antigens. Hence, further studies
are needed to examine how the nature of the antigen used in
neuroprotective vaccines affects the efficacy of the treatment.
Current treatments for Parkinson’s disease (PD) temporarily
ameliorate its symptoms but do not slow progressive loss of
dopaminergic neurons. Accordingly, new approaches to slow the
degeneration of the nigrostriatal dopaminergic system are urgently
needed. It is thought that oxidative stress, protein nitration and
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activated microglia contribute to the loss of dopaminergic function
in human PD [17,18,19,20]. Additionally, there is a growing
appreciation that CD8+ and CD4+ T cells significantly infiltrate
the SN of patients with PD [21,22]. All of these potentially
pathogenic factors are elicited by treatment with the neurotoxin
MPTP [23,24,25]. The MPTP mouse model of PD has therefore
been extensively used to assess neuroprotective strategies. Several
studies have shown that vaccination with oligodendrocyte antigens
or CopaxoneH in CFA preserves dopaminergic neurons in MPTP-
treated mice [10,26,27,28]. These studies, however, did not
determine whether the vaccine-induced immune responses limited
the initial nigrostriatal dopamine system damage and/or promot-
ed long-term neurorestoration.
We began our studies asking whether vaccination with tyrosine
hydroxylase (TH), a neuronal protein involved in dopamine
synthesis, could protect striatal dopaminergic neurons to a greater
extent than CopaxoneH in the MPTP model of PD in mice.
Contrary to our expectations, we observed that immune stimulation
by the CFA adjuvant, regardless of the emulsified antigen, appeared
to be the major neuroprotective factor. CFA contains inactivated
Mycobacterium tuberculosis in mineral oil and is unsuitable for human
use. The BCG vaccine developed against childhood tuberculosis
contains live attenuated Mycobacterium bovis that is closely related to
Mycobacterium tuberculosis, and has been administered safely to billions
of individuals since the 1920s [29,30]. We describe the neuropro-
tective effects of BCG vaccination in the MPTP mouse model and
discuss possible underlying mechanisms. Our results suggest that
general (nonself-reactive) immune stimulation in the periphery may
provide a new strategy to help slow disease progression in some
neurodegenerative diseases.
Materials and Methods
Animals
All studies were approved by the UCLA Chancellor’s Animal
Research Committee (approval #2000-023-33). Male C57BL/6J
mice (Jackson Laboratory), 8–10 weeks in age were used in all
studies.
Antigens for vaccination
We subcloned a mouse TH cDNA into a bacterial expression
vector (pET-15b, Novagen) which directed the expression of TH
with a short polyhistidine tag on it’s carboxy terminus, and
purified the TH from IPTG-induced recombinant E.coli inclusion
bodies using nickel affinity chromatography. The eluted proteins
were further separated using preparative SDS-PAGE and the
band corresponding to TH was excised, electroeluted and the
protein dialyzed into saline and frozen at 280u C until use.
CopaxoneH was purchased from TEVA Pharmaceutical Indus-
tries. BCG (TheraCysH) was purchased from Sanofi Pasteur.
Vaccinations
Mice were vaccinated with the indicated antigen (100 mg) in
CFA (1 mg/ml mycobacteria) in 0.10 ml subcutaneously at base
of tail. Other mice were vaccinated with live BCG (26107 cfu)
intraperitoneally (i.p.).
MPTP treatment
Ten days after vaccination, mice were injected with 20 mg/kg
MPTP i.p. for 5 consecutive days as previously described [31,32].
WIN binding assays
[3H]WIN 35,428 (WIN, 87.0 Ci/mmol) was obtained from
Perkin Elmer Life Sciences (Boston, MA). All other chemicals were
obtained from Fisher Scientific (Pittsburgh, PA). Mice were killed
by decapitation; the brains were removed and sectioned into 1-
mm coronal slices with a mouse brain mold on ice. Left and right
striatal tissues were dissected out on an ice-cold stainless steel plate
to constitute 2 samples which were frozen in dry ice and stored at
280uC until analysis. One striatal sample was used to measure
[3H]WIN 35,428 binding to the dopamine transporter (DAT) in a
homogenate preparation, according to our previously published
methods [33].
HPLC-EC analysis of dopamine content
The remaining striatal sample from individual mice was
homogenized by ultrasonication in 0.5 ml ice-cold 0.2M HClO4
containing 0.15% (w/v) Na2S2O5 and 0.05% (w/v) Na2EDTA
and centrifuged at 14,000 rpm for 15 min at 4uC. The
supernatants were filtered through a 0.2 mm PTFE filter; the
pellet was analyzed for protein content. An aliquot of 20 ml filtrate
was used for HPLC-EC analysis of dopamine (DA) as previously
described [34].
Stereological analysis of Iba1+ microglia cell and TH+ cell
numbers in the substantia nigra
Serial transverse sections of mouse midbrain were cryosectioned
(30 mm using a Leica CM1850) and every fourth serial section was
immunostained with anti-Iba1 (1:500, WAKO Chemicals) and
visualized by using the chromogen diaminobenzidine. The
number of Iba1+ microglia in the substantia nigra pars compacta
(SNc) were counted using an Olympus BX40 microscope and
StereoInvestigator software (MicroBrightField). In brief, the two
parts of the SNc were delineated on each section with 46objective
lens by an investigator who was blinded to the treatment. The
counting was performed using optical fractionator formula [35]
and a 1006 oil lens. Representative images of Iba1+ cells were
taken using a 1006oil lens on an Olympus BX50 microscope and
an Insight Firewire 14.2 Color Mosaic digital camera (Diagnostic
Instrument Inc.) using Metamorph 8.0 software.
Stereological analysis of TH+ cells in the SNc was conducted in
a similar manner, with every fourth serial section immunostained
with anti-TH antibody (1:1000, Calbiochem-Novabiochem
Corp., San Diego) and visualized by using the chromogen
diaminobenzidine.
Statistical analysis
All values are expressed as group mean 6 SEM. Differences
among groups were analyzed by one-way ANOVA, followed by
post hoc Student’s t-test for pair-wise comparison. The null
hypothesis was rejected at p#0.05.
Results
CFA is the major beneficial component of
neuroprotective vaccines in the MPTP mouse model
Studies of neuroprotective vaccines have focused on using
CopaxoneH since it induces protective immune responses that
cross-react with myelin antigens and because it is in clinical use for
treating MS. We wanted to test whether immunization with a
dopaminergic neuron antigen might have a more beneficial effect
in the MPTP mouse model of PD, since this should direct vaccine-
induced T cells to the brain areas that were damaged by MPTP
treatment and that slowly degenerate in human PD. We chose
tyrosine hydroxylase as a test antigen because it is involved in
dopamine synthesis and is predominantly expressed in striatal
dopaminergic neurons. We isolated TH from recombinant E. coli
BCG Vaccine-Induced Neuroprotection
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inclusion bodies, and purified it using affinity chromatography and
preparative SDS-PAGE as described in Materials and Methods.
Gel analysis of the purified TH is shown in Supplement Figure S1.
Since it takes 10–14 days for vaccine-induced immune responses
to peak, and MPTP has a very immediate toxic effect, we
immunized mice with TH or CopaxoneH in CFA (TH/CFA and
CopaxoneH/CFA, respectively) 10 days before MPTP treatment.
A group of control mice received only saline. The animals were
sacrificed 21 days after the last MPTP treatment, which is a
relatively long time point for such studies, because we wanted to
test for potential neurorestorative effects of vaccination. As an
initial read-out of the vaccine’s ability to preserve dopaminergic
system integrity, we measured [3H]WIN 35,428 (WIN) binding to
DAT in mouse striatal homogenates.
We found that the mean DAT WIN binding levels were higher
in striata from MPTP-treated mice that received CFA, regardless
of whether they received CFA alone, TH/CFA, or CopaxoneH/
CFA, compared to that in unvaccinated MPTP-treated mice
(Fig. 1). Specifically, compared to unvaccinated MPTP-treated
mice, the levels of striatal WIN binding were 43% higher in
MPTP-treated mice that received CFA alone (p,0.01) and 34%
higher in mice that received CopaxoneH/CFA (p,0.05). The level
of striatal WIN binding was 17% higher in MPTP-treated mice
that received TH/CFA, but this was not statistically significant.
These results argue against our initial hypothesis that a neuronal
self-antigen may provide a more efficacious neuroprotective
vaccine. Rather, the results suggest that peripheral immunostim-
ulation by CFA was the major beneficial factor.
CFA vaccination promotes neurorestoration
It is possible that immune responses elicited by CFA vaccination
limited MPTP’s direct effects or promoted the subsequent
restoration of dopaminergic neuron integrity. We therefore
performed a more detailed study of the effects of CFA
immunization on DAT levels 4 and 21 days after the last MPTP
treatment.
Groups of mice were vaccinated with CFA (alone) or saline, and
10 days later were given MPTP for 5 consecutive days. Four days
after the last MPTP treatment, the mean levels of striatal WIN
binding were 18% higher in the CFA treated group than in
unvaccinated MPTP-treated mice, but this increase was not
statistically significant (Fig. 2.). This suggests that CFA vaccination
did not differentially affect the uptake, distribution or metabolism
of MPTP and that CFA-induced immune responses have little or
no ability to limit the acute toxicity of MPTP.
We also examined similarly treated mice 21 days after the last
MPTP treatment. We found that the mean levels of striatal DAT
WIN binding was 29% higher in CFA vaccinated mice that
received MPTP, compared to unvaccinated MPTP-treated mice
(Fig. 2, p,0.01). These data again demonstrate the beneficial
effects of CFA (alone) treatment in our model. Additionally, the
increase in striatal WIN binding observed in vaccinated vs.
unvaccinated MPTP-treated mice from 4 to 21 days post-
treatment (18% and 29%, respectively), suggests that CFA
treatment promoted a greater rate of neurorestoration. Indeed,
21 days after MPTP treatment, only CFA-treated mice displayed a
significant increase in striatal DAT WIN binding compared to
levels 4 days post-treatment, suggestive of a neurorestorative effect.
BCG vaccination partially preserves striatal DA and DAT
in MPTP-treated mice
CFA is unsuitable for human use, but its main immunogenic
component, inactivated Mycobacterium tuberculosis, is closely related
to the live attenuated Mycobacterium bovis used in the BCG vaccine
against childhood tuberculosis. We hypothesized that the periph-
eral immune responses induced by BCG immunization may also
be neuroprotective.
C57Bl/6 mice were immunized with BCG and 10 days later
they, and a control group of unvaccinated mice, received MPTP.
Twenty one days later, their striatal WIN binding levels were
measured. Mice vaccinated with BCG had significantly higher
levels of WIN binding than MPTP controls (26% higher, P = 0.05,
Figure 1. Vaccination with CFA preserves striatal DAT binding
in MPTP-treated mice. Groups of mice were vaccinated with CFA
(alone), CopaxoneH/CFA or TH/CFA prior to MPTP treatment. Twenty
one days after the last MPTP treatment, striatal DAT levels were
assessed using a [3H]WIN-35,428 binding assay. Data shown are mean
[3H]WIN-35,428 binding6SEM to striatal homogenate. N= 6–8 mice/
group. *p,0.05, **p,0.01 vs. MPTP (alone) by Student’s t-test.
doi:10.1371/journal.pone.0016610.g001
Figure 2. Higher striatal DAT binding in CFA-vaccinated mice
21 days post-MPTP-treatment. A control group of non-vaccinated
mice received MPTP only (open bars) and another group of mice
received BCG prior to MPTP treatment (black bars). Mice were sacrificed
4 or 21 days after the last MPTP treatment and their striatal DAT binding
capacity was determined. Data shown are [3H]WIN-35,428 (mean6SEM)
binding to striatal tissue homogenate (n = 7–8 mice/group) in two
independent experiments. *p = 0.05, **p,0.01 by two-way ANOVA.
doi:10.1371/journal.pone.0016610.g002
BCG Vaccine-Induced Neuroprotection
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Fig. 3A). In addition, striatum from mice vaccinated with BCG
also had significantly higher DA content (16% higher than MPTP
controls, p,0.01, Fig. 3B). Thus, BCG vaccination had a
significant beneficial effect on both striatal DA content and
DAT ligand binding levels.
BCG vaccination prevents an increase in the number of
activated microglia in the substantia nigra following
MPTP treatment
Previous studies have shown that the number of microglia
increases rapidly in the striatum after MPTP treatment and play
an active role in MPTP-induced nigro-striatal system damage
[24,36,37,38,39,40,41,42]. Inflammatory type microglia are con-
sidered detrimental to neuron survival after a neuro-toxin insult
[36] and blockade of microglia activation was neuroprotective in
the MPTP mouse model of PD [24,37,38,39,40,41,42].
To examine whether BCG vaccination also affected the
microglial reaction to MPTP toxicity, we treated other groups of
mice with BCG or saline prior to MPTP treatment and counted
the number of microglia in their midbrains three days post-MPTP
treatment. We found that the number of Iba1+ microglia cells was
significantly greater in animals that received MPTP compared to
that in mice that received only saline (Fig. 4A), as also reported by
others (e.g., [10,24,37]). In contrast, the Iba1+ cell number in SNc
of BCG-vaccinated mice that received MPTP was similar to that
in mice that only received saline (Fig. 4A). We also observed that
the Iba1+ cells in the unvaccinated MPTP-treated mice had large
cell bodies with only a few short thick processes, a morphology
associated with microglia activation. In contrast, the Iba1+ cells in
mice that received BCG before MPTP treatment had small cell
bodies with long-fine processes similar to those in saline-treated
control mice, suggesting a resting state (representative images in
Figs 4B–D) [10,13]. Thus, BCG vaccination prevented the MPTP-
induced increase in the number of activated microglia in the SNc,
suggesting that general immune stimulation in the periphery can
limit CNS microglia responses to a neuronal insult.
At 21 days post-MPTP, stereological analysis revealed that the
number of TH+ cells in the SNc of animals that received BCG was
on average 6% greater than that in mice that received only MPTP
(64006424 vs. 60346321, respectively), although this was not
statistically significant (n = 6 and 7 mice/group, respectively).
Discussion
Vaccination with CNS antigens has beneficial effects in a number
of different animal models of neurological disease and injury. This
strategy is based on inducing CNS-reactive T cells which home to
areas of damage and exert beneficial effects locally in a process
termed ‘‘protective autoimmunity’’ [1]. Early studies of neuropro-
tective vaccines administered myelin antigens, which raised safety
concerns because of their potential for inducing a MS-like disease.
Subsequent studies used CopaxoneH which has some resemblance
with MBP, and in its aqueous form is approved for MS treatment.
Almost all these studies, however, used CFA as an adjuvant and
often did not report on the effects of CFA alone. The studies that did
examine CFA (alone) often reported that these treatments had some
beneficial effect, although of lower magnitude than the myelin
antigen or CopaxoneH in CFA [10,26,43,44].
Contrary to our initial expectations, we found that immuniza-
tion with a dopaminergic neuron antigen did not provide a greater
beneficial effect. Rather, CFA itself appeared to be main factor
associated with higher levels of striatal WIN binding in vaccinated
MPTP-treated mice. CFA treatment did not significantly alter the
level of striatal DAT WIN binding 4 days after MPTP treatment,
suggesting that CFA-induced immune responses cannot limit the
acute toxicity of MPTP. Twenty one days post-MPTP treatment,
however, the average levels of striatal DAT WIN binding in CFA
treated MPTP-treated mice was significantly greater than that in
unvaccinated MPTP-treated mice. The ratio of striatal WIN
binding in vaccinated mice versus unvaccinated MPTP-treated
mice increased from 4 to 21 days, suggesting that the CFA-
induced responses promoted a greater rate of neurorestoration.
CFA-treated mice, but not unvaccinated mice, had significantly
higher striatal WIN binding 21 days vs. 4 days after MPTP
treatment, indicating a neurorestorative effect.
Based on the neuroprotective effects of CFA, we turned to testing
BCG vaccination. Potential advantages of BCG vaccination include
not only its established safety record over many decades of
worldwide use in humans, but also that the attenuated BCG slowly
replicates in the vaccinated individual, inducing immune responses
over many months. Accordingly, BCG vaccination could provide a
long-term source of neurosupportive immune responses.
Figure 3. BCG vaccination preserves DAT-ligand binding and
DA levels in MPTP-treated mice. Mice were vaccinated with BCG, or
administered saline, prior to MPTP treatment. Twenty one days after the
last dose of MPTP we analyzed striatal [3H] WIN-35,428 binding (A) and
DA levels (B). Results from two independent experiments were pooled
(total 16–18 mice in each group). Data shown are mean6SEM. *p,0.05,
**p,0.01 by two-tailed t-test.
doi:10.1371/journal.pone.0016610.g003
BCG Vaccine-Induced Neuroprotection
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We observed that BCG vaccination significantly preserved striatal
DAT WIN binding and DA content compared to that in
unvaccinated MPTP-treated mice. Usually, MPTP treatment causes
an increase in the number of nigral microglia, which may be due to
resident microglia replication, or the influx of bone-marrow-derived
cells (BMDCs, a macrophages or microglia precursors) from the
periphery [45,46,47]. The increased number of activated microglia in
the SNc is thought to contribute to MPTP-induced nigrostriatal
system damage (e.g., [24,37,38,39,40,41,42,46,47].). Consistent with
those reports, we observed that MPTP-treated mice displayed a
greater than 2-fold increase in the number of Iba1+ cells in
their SNc. In contrast, mice that were treated with BCG prior
to MPTP treatment had a similar number of SNC Iba1+ cells
to that in saline-treated control mice. In addition, in BCG
treated mice, the nigra microglia had small cell bodies and long
ramified processes, indicating a resting state. Such microglia are
thought to exert neurosupportive functions by their abilities to
produce neurotrophins and eliminate excitotoxins [13,48]. These
observations parallel previous assessments of microglia in
MPTP-treated mice that received an adoptive transfer of spleen
cells from CopaxoneH/CFA vaccinated mice [10]. However, our
results show that peripheral BCG-induced immune responses
are sufficient to almost completely inhibit the MPTP-induced
increase in activated microglia number in the SNc. Conceivably,
by circumventing the MPTP-induced increase in activated
microglia and the accompanying proinflammatory milieu, the
surviving dopaminergic neurons were better able to recover
function in BCG-treated mice. Further studies will be necessary
to establish how the marked alterations in microglia morphology
and activation affect long-term nigrostriatal dopamine system
integrity.
Proposed mechanisms for neuroprotective vaccines have been
contradictory in regard to whether Th1, Th2, Th3 and/or Treg
cells play beneficial or pathogenic roles. Some of these differences
may be due to the different disease models studied. Focusing on
studies of immune-mediated protection in the MPTP mouse PD
model, recent studies have pointed to CD4+ T cells as playing a
key role in neurodegeneration [22]. Th17 cells recognizing
nitrated a-synuclein can exacerbate MPTP-induced neuronal cell
loss, but can be held in check by Tregs [41,49]. The immune
responses elicited by CFA and BCG have been extensively studied
and they are both potent inducers of IFNc-secreting Th1-type
CD4+ T cells and activators of antigen presenting cells (APCs)
[50,51,52]. IFNc is known to antagonize the development of Th17
cells [53,54] and can induce apoptosis of self-reactive T cells [55].
Additionally, BCG or Mycobacterium tuberculosis infection induces
Tregs that proliferate and accumulate at sites of infection, which
contribute to limiting inflammatory responses and tissue damage
during infection [56,57,58,59]. Accordingly, the Th1 and Treg
responses may have suppressed the priming and expansion of
Teffector cells following MPTP treatment. It is possible that the
robust T cell responses to BCG also created greater T cell
Figure 4. BCG vaccination prevents the MPTP-induced increase of microglia in the substantia nigra. Serial midbrain sections from mice
that were, or were not, treated with BCG or MPTP were stained with anti-Iba1 antibody. A). Quantitative analysis of Iba1+ microglia. Data are
represented as mean6SEM. (*p,0.05 by two-tailed t-test) N= 4–6 mice/group. B). Representative micropraghs of Iba1+ cells in the substantia nigra
of mice treated only with saline (B), MPTP only (C), and BCG+MPTP (D). Note small cell body and long ramified processes of the Iba1+ cells in the
saline (B) and BCG-vaccinated MPTP-treated mice (D), in contrast to the larger cell body with few processes in MPTP treated mice (C). Scale
bar = 10 mm.
doi:10.1371/journal.pone.0016610.g004
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competition for APC that reduced the priming of Teffector cells in
the periphery.
Another possible protective mechanism is that the active BCG
infection in the periphery diverted Teffectors, macrophages and
BMDC microglia precursors from entering the CNS after MPTP
treatment. Previous studies in the experimental autoimmune
encephalomyelitis (EAE) model have shown that infection with
BCG 6 weeks before the induction of EAE diverts activated
myelin-reactive CD4+ T cells from the CNS to granulomas in the
spleen and liver [60]. This diversion was not due to cross-reactivity
between BCG antigens and encephalitogenic proteins [61].
Evidently, the peripheral inflammatory lesions non-specifically
attracted Teffectors that blunted the development of EAE.
Interestingly, in clinical trials, MS patients immunized with
BCG had a 57% reduction of lesions as measured by MRI
[62,63]. Thus, there is some clinical evidence that BCG treatment
can suppress a neurodegenerative autoimmune response.
Based on our observations that MPTP did not increase
microglia number and that microglia were in a resting state in
the nigra of BCG-vaccinated mice, it is possible that the BCG
treatment circumvented the activation and replication of resident
microglia, diverted macrophage or BMDC microglia precursors
from entering the CNS, and/or induced some efflux of
macrophage-type cells to the periphery. Another possible
protective mechanism is that the long period during which the
attenuated BCG slowly replicates in the host causes a long-term
increase in the levels of circulating immune factors (e.g., cytokines,
chemokines or other factors), many of which can enter the CNS
[64]. These immune factors may have limited microglia activation
and proliferation, the influx of peripheral macrophages or
microglia precursor cells, or had a supportive effect on neurons
in the area of injury. Further testing is required to distinguish
among these possibilities.
There are additional lines of evidence that peripheral immune
responses can modulate the CNS milieu. Many studies have shown
that treatment of pregnant rodents with immuno-stimulants such
as lipopolysaccharide, polycytidylic acid, turpentine or viral
infection, cause the offspring to have behavioral abnormalities
(reviewed in [65,66]). It is thought that the maternal immune
responses to these treatments can alter neurodevelopment in the
fetus. These studies provide further evidence that peripheral
immune responses can modulate the CNS milieu independently of
CNS-reactive T cells.
While the exact mechanisms of BCG neuroprotection in the
MPTP mouse model remain to be elucidated, our results suggest
that peripheral BCG-induced immune responses can exert
neuroprotective effects independent of CNS antigen-specify. This
represents a paradigm shift from the current notion that
neuroprotective vaccines work by inducing protective T cell
autoimmunity that acts locally in damaged areas in the CNS. It
will be of interest to transfuse GFP-marked BMDC and T cells
into mice prior to BCG and MPTP treatments in order to further
study BCG’s protective mechanisms.
Is there epidemiological evidence that BCG vaccination could
be neuroprotective? BCG vaccinations were discontinued in the
USA in the 1950s largely because of the low incidence of TB and
the vaccine’s incomplete protection. However, BCG vaccination is
still given to infants and children in many countries. Adults who
were BCG vaccinated as children have little/no protection from
TB. Because BCG vaccine effects have greatly diminished by
middle age, we would not expect to find a relationship between
childhood BCG vaccination and PD incidence. Moreover, the
BCG vaccine-mediated protection from TB relies on a small
population of memory T cells that is quiescent and that only
expands after re-exposure to TB. Since PD patients are not
normally exposed to active TB, their few BCG-reactive memory T
cells should be quiescent and would not be a source of
neuroprotective factors.
While neuroprotective vaccines cannot correct basic intrinsic
neuronal deficits, they may alter the CNS environment to be more
neurosupportive so that neurodegeneration and secondary dam-
age to neurons progresses at a slower rate. Conceivably, BCG-
induced neuroprotective immune responses will be more beneficial
in a slowly progressing disease, as in human PD, than in the
acutely neurotoxic MPTP model we have studied.
In summary, our data show that BCG vaccination, which is safe
for human use, can preserve striatal dopaminergic markers. This
strongly supports the notion that peripheral immune responses can
be benifical in neuropathological conditions. Second generation
recombinant BCG vaccines, which have greater immunogenicity
and are expected to elicit enhanced immunity against TB, are now
being tested in clinical trials. Some new recombinant BCG strains
express a human cytokine to boost desired immune responses. It
will be of interest to test whether different recombinant BCG
strains can enhance the vaccination’s neuroprotective effects.
Further studies of how peripheral immune system responses can
modulate neurons and glia in the CNS may provide new
therapeutic strategies to safely slow neurodegenerative disease
processes.
Supporting Information
Figure S1 SDS-PAGE analysis of purified recombinant
TH. Image of a silver-stained gel in which the left lane was loaded
with molecular weight markers and the right lane was overloaded
with purified TH.
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